Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Exagen Inc

XGN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Healthcare Facilities & Services ·

USA Micro Cap Analyst: BUY

Last Close

$6.66

▲ +1.22%

Market Cap $161.34M · Vol 53.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$161.34M

Micro Cap

Div Yield

N/A

EPS Growth

+30.42%

YoY

RSI (14)

80.54

Momentum

Beta

2.17

vs Market

52W High

$12.11

45.00% below

52W Low

$2.60

156.15% above

Volume

53.14K

Avg 95.71K

P/B

7.98

Price-to-book

ROE

-147.85%

Return on equity

Free Float

57.48%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Exagen Inc (XGN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.06%

+62.84%

+72.99%

+103.05%

YTD

+9.54%

-28.73%

+162.20%

-45.77%

Financials & Valuation

TTM · Annual

Total Revenue	$66.58M
Net Income	$-19,951,000.00
Revenue Growth (YoY)	+15.92%
Gross Margin	58.28%
Operating Margin	-21.13%
Net Profit Margin	-29.97%
ROE	-147.85%
ROA · ROIC	-38.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.97
P/B	7.98
P/FCF	N/A
EPS Growth	+30.42%
Outstanding Shares	24.23M

Technical Indicators

50-Day SMA	$4.90
200-Day SMA	$5.00
RSI (14)	80.54
Beta	2.17
52-Week High	$12.11
52-Week Low	$2.60

Volume Today	53.14K
Avg Daily Volume (30D)	95.71K
Relative Volume	0.56x
Volatility (10D)	153.51
Volatility (30D)	113.72
Free Float	57.48%

Analyst Consensus

BUY

Current Price $6.66

Mean Target $9.86

52W Low$2.60 52W High$12.11

Current

Target

$2.60 $12.11

Current Analyst target

+48.01% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001TCQVF6

ISINUS30068X1037

CountryUnited States of America

Sub-IndustryMedical & Diagnostic Laboratories

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

NTRA Natera Inc -0.27% LH Labcorp Holdings Inc -1.38% RDNT RadNet Inc -1.24% LALPATHLAB.NS Dr. Lal PathLabs Ltd -2.65% WGS GeneDx Holdings Corp -1.35%

Company Profile

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.